Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMethoxyluteolin
说明： Inhibitor of pro-inflammatory mediator release from mast cells
化学名： 2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4H-1-benzopyran-4-one
纯度： ≥98% (HPLC)
生物活性 for Methoxyluteolin
Methoxyluteolin inhibits release of pro-inflammatory mediators from mast cells and decreases gene expression and release of TNF, VEGF and IL-8/CXCL8. The product also significantly inhibits IL-33 stimulated expression and release of CCL5 and CCL2. Methoxyluteolin pretreatment of LAD2 mast cells decreases gene expression of TNF, CXCL8 and VEGF in response to neurotensin or substance P via mTOR activation.
技术数据 for Methoxyluteolin
| 分子量 | 342.35 |
| 公式 | C19H18O6 |
| 储存 | Store at -20°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 855-97-0 |
| PubChem ID | 631170 |
| InChI Key | CLXVBVLQKLQNRQ-UHFFFAOYSA-N |
| Smiles | O=C1C=C(OC2=CC(OC)=CC(OC)=C12)C=3C=CC(OC)=C(OC)C3 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for Methoxyluteolin
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 6.85 | 20 |
制备储备液 for Methoxyluteolin
以下数据基于产品分子量 342.35。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.2 mM | 14.6 mL | 73.02 mL | 146.05 mL |
| 1 mM | 2.92 mL | 14.6 mL | 29.21 mL |
| 2 mM | 1.46 mL | 7.3 mL | 14.6 mL |
| 10 mM | 0.29 mL | 1.46 mL | 2.92 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for Methoxyluteolin
参考文献 for Methoxyluteolin
参考文献是支持产品生物活性的出版物。
Abubakr Bawazeer and Theoharides (2019) IL-33 stimulates human mast cell release of CCL5 and CCL2 via MAPK and NF-κB, inhibited by methoxyluteolin. Eur.J.Pharmacol. 865 PMID: 31669588
Weng et al (2015) The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J.Allergy Clin.Immunol. 135 1044 PMID: 25498791
Patel and Theoharides (2017) Methoxyluteolin inhibits neuropeptide-stimulated proinflammatory mediator release via mTOR activation from human mast cells. J.Pharmacol.Exp.Ther. 361 462 PMID: 28404689
Taracanova et al (2018) Substance P and IL-33 administered together stimulate a marked secretion of IL-1β from human mast cells, inhibited by methoxyluteolin. Proc.Nat.Acad.Sci. USA 115 9381 PMID: 30232261
If you know of a relevant reference for Methoxyluteolin, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: Methoxyluteolin, Methoxyluteolin supplier, methoxyluteolin, mast, cells, inhibitors, inhibits, cytokines, Cytokines, 7320, Tocris Bioscience
篇 Methoxyluteolin 的引用文献
引用文献是使用了 Tocris 产品的出版物。
目前没有 Methoxyluteolin 的引用文献。 您是否知道使用了 Tocris Methoxyluteolin 的优秀论文？ 请告知我们.
Methoxyluteolin 的评论
目前没有该产品的评论。 Be the first to review Methoxyluteolin and earn rewards!
Have you used Methoxyluteolin?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.